- Home
- EML vs PBYI Comparison
EML vs PBYI Comparison
Compare EML & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- PBYI
- Stock Information
- Founded
- EML 1858
- PBYI 2010
- Country
- EML United States
- PBYI United States
- Employees
- EML N/A
- PBYI N/A
- Industry
- EML Industrial Machinery/Components
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- EML Consumer Discretionary
- PBYI Health Care
- Exchange
- EML Nasdaq
- PBYI Nasdaq
- Market Cap
- EML 144.0M
- PBYI 164.3M
- IPO Year
- EML N/A
- PBYI N/A
- Fundamental
- Price
- EML $24.46
- PBYI $3.45
- Analyst Decision
- EML
- PBYI Strong Buy
- Analyst Count
- EML 0
- PBYI 1
- Target Price
- EML N/A
- PBYI $7.00
- AVG Volume (30 Days)
- EML 11.8K
- PBYI 307.3K
- Earning Date
- EML 08-05-2025
- PBYI 07-31-2025
- Dividend Yield
- EML 1.80%
- PBYI N/A
- EPS Growth
- EML N/A
- PBYI 143.51
- EPS
- EML N/A
- PBYI 0.77
- Revenue
- EML $271,440,503.00
- PBYI $232,709,000.00
- Revenue This Year
- EML $1.56
- PBYI N/A
- Revenue Next Year
- EML $7.00
- PBYI N/A
- P/E Ratio
- EML $11.67
- PBYI $4.43
- Revenue Growth
- EML 8.15
- PBYI 2.68
- 52 Week Low
- EML $19.06
- PBYI $2.23
- 52 Week High
- EML $35.03
- PBYI $4.13
- Technical
- Relative Strength Index (RSI)
- EML 62.18
- PBYI 50.12
- Support Level
- EML $24.04
- PBYI $3.26
- Resistance Level
- EML $24.70
- PBYI $3.68
- Average True Range (ATR)
- EML 0.55
- PBYI 0.12
- MACD
- EML 0.13
- PBYI 0.00
- Stochastic Oscillator
- EML 91.74
- PBYI 52.90
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.